Three-year Low-dose Menaquinone-7 Supplementation Helps Decrease Bone Loss In Healthy Postmenopausal Women
Notes for this study:
|Number of Subjects
180μg of MK-7 daily for a period of three years in otherwise healthy postmenopausal women was able to increase circulating carboxylated osteocalcin (21+/-19% increase seen with MK-7 and none in placebo) and decreased the uncarboxylated osteocalcin (51+/-21%) within one year (maintained for two years) which was associated with a preservation of femoral and spine bone mineral density (no influence on hip) and increase in bone strength, there were less fractures associated with MK-7 relative to placebo.
Funding issues for this study:
Funded by Nattopharma, producer of the MK-7 capsules used; no conflict of interest apparent